Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia

Published:2023-07-27 Issue:9 Volume:16 Page:633-639
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Huguet Françoise¹²,Réa Delphine²³,Cayssials Emilie²⁴,Etienne Gabriel²⁵,Nicolini Franck-Emmanuel²⁶

Affiliation:

1. Hematology Department, Institut Universitaire du Cancer, Centre Hospitalier Universitaire, Toulouse, France

2. Fi-LMC Group, Lyon, France

3. Hematology Department, Hôpital Saint-Louis, Assistance Publique, Hôpitaux de Paris, France

4. Hematology Department, Centre Hospitalier Universitaire, Poitiers, France

5. Hematology Department, Institut Bergonié, Bordeaux, France

6. Hematology Department, Centre Léon Bérard, Lyon, France

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2023.2234084

Reference56 articles.

1. Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis

2. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?

3. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel

4. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

5. Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP